biotech

What Does It Take to Swing the IPO Window Open for Biotechs? – Suggestions include selling at a discount at a time when there is a rising investor fan-base for social media.

By Claremont Creek Alerts / June 22, 2011 / 0 Comments

June 22, 2011  source: Genetic Engineering and Biotechnology News On June 10, a day after withdrawing an $86 million IPO filed in November 2010, Ambit Biosciences reported securing $30 million in Series D-2 equity financing. “The terms currently obtainable in the public marketplace are not sufficiently attractive to the registrant to warrant proceeding with the […]

Read More

Meet our team

Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.

Nat_Boldhaber7718 -1200px

NAT GOLDHABER

Nat Goldhaber is a co-founder of Claremont Creek Ventures. 

READ MORE
Brad_Webb8124 1200px crop

BRAD WEBB

Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.

READ MORE
Randy_Hawks7690 -1200px

RANDY HAWKS

Randy Hawks is a co-founder of Claremont Creek Ventures.

READ MORE

Post Categories

Keywords

energy storage bioinformatics market uncertainty targeted customer segments Series B genetic screening Digital Healthcare Personalized Pharmacology startups market conditions carried interest swtching costs bionics awards innovation corporate venture funding power generation cleantech gene disorder testing private equity stem cell renewable energy chromosone screening IPO solar energy tech exit cloud computing words-of-wisdom mentoring early-stage M&A funding angel investor healthcare energy conservation video government programs greentech SVASE DOOH smartgrid government funding government policies thermoelectric

Archives